Results for announcement to the market Name of entity: Anteris Technologies Global Corp. ("ATGC") ARBN: 677 960 235 Reporting period: For the quarter ended

Results for announcement to the market

The attached Form 10-Q Quarterly Report for the quarter ended September

30, 2025 has been filed with the U.S. Securities and Exchange Commission. It includes the condensed consolidated financial statements which have been prepared in accordance with generally accepted accounting principles in the United States of

America ("U.S. GAAP") and are denominated in U.S. dollars.

The following supplementary information is provided in connection with the Form 10-Q for the purposes of compliance with ASX Listing Rule 4.7C in

relation to quarterly activity reports. This information should be read in conjunction with the Form 10-Q and is provided to satisfy the Company's ongoing disclosure obligations under the ASX Listing Rules.

Details of business activities during the quarter:

Refer to the Form 10-Q and the "Anteris Announces Results for the Third Quarter of 2025" announcement lodged with the ASX on November 13, 2025.

On December 12, 2024, our registration statement on Form S-1 relating to our initial public offering became effective pursuant to which we issued

and sold 14,878,481 shares of Common Stock. We received net proceeds of US$80.0 million, after deducting the underwriting discounts, commissions and offering expenses and giving effect to the exercise of the underwriters' option to purchase

additional shares. The use of proceeds from our initial public offering, as of September 30, 2025, was as follows:

Aggregate amount of payments to related parties and their associates:

During the third quarter of 2025, the aggregate amount of payments to related parties and their associates (which includes director fees, Company

secretarial fees, CEO, President and CFO remuneration) was US$515 thousand. These payments were included in cash flows from operating activities.

There were no payments to related parties or their associates included in cash flows from investing activities.

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and

commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals

delivering restorative solutions to structural heart disease patients.

Anteris' lead product, the DurAVR Transcatheter Heart Valve (THV), was designed in collaboration with the world's leading interventional

cardiologists and cardiac surgeons to treat aortic stenosis - a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR

THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR THV is made using a single piece of molded ADAPT tissue,

Anteris' patented anti-calcification tissue technology. ADAPT tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR THV System is

comprised of the DurAVR valve, the ADAPT tissue, and the balloon-expandable ComASUR Delivery System.

Authorisation and Additional information

This announcement was authorised for release on the ASX by the Board of Directors.

For more information: